
Bajaj Healthcare’s stock jumped 12% following its announcement of securing exclusive rights for the manufacturing, distribution, and sales of Magnesium L Threonate (Magtein®) in India. The company signed an agreement with Threotech LLC, the rights holder of the innovative product.
This deal also grants Bajaj Healthcare the ability to forge marketing collaborations with top pharmaceutical firms in India, expanding its market presence. Additionally, Bajaj already supplies the API of Magnesium L Threonate (Magtein®) to Threotech LLC in the U.S. The product has generated around USD 438 million in sales in the U.S.
Bajaj Healthcare’s shares opened at ₹579.00, with a session high of ₹654.00 and a low of ₹579.00. Over the past 52 weeks, the stock has reached a high of ₹654.45 and a low of ₹263.30, reflecting significant price fluctuations.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.